Racura Oncology raises $34.3 million in a funding round to advance its clinical programs in cancer treatment.
PRIVATEJun 17, 2026
Amount Raised
$34.3 Million
Round Type
Funding Round
SydneyBiotechnologyHealth CareMedicalTherapeutics
Description
Racura Oncology has secured $34.3 million following a series of fundraising initiatives supported by new and existing shareholders. This funding will enable the company to fully finance its RC220 clinical programs. These programs focus on Acute Myeloid Leukaemia, EGFRm non-small cell lung cancer, and anthracycline cardioprotection. The additional funds provide a strong cash balance for the company's ongoing research efforts.
Company Information
Company
Racura Oncology
Location
Sydney, New South Wales, Australia
About
Racura Oncology is a biopharmaceutical company focused on developing innovative treatments for cancer. The company is advancing several clinical programs, notably in Acute Myeloid Leukaemia and non-small cell lung cancer. Racura is also exploring treatments aimed at cardioprotection in solid tumor patients. With significant fundraising success, Racura is positioned to enhance its clinical trials.
Fundz sees it the moment Racura Oncology raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
SydneyBiotechnologyHealth CareMedicalTherapeutics